China’s CDE grants breakthrough status approval to Abbisko’s HCC therapy
The CDE’s decision is supported by encouraging data from the Phase I trial.
Therapy Area
CHMP recommends GSK’s Blenrep approval for multiple myeloma treatment
ASCO25: Roche’s Itovebi combo reduces risk of death in breast cancer by 33%
Bayer’s Eylea set for longer treatment intervals to challenge Roche’s Vabysmo
FDA approves GSK’s Nucala to treat COPD
Sanofi buys Vigil Neuroscience for $470m in Alzheimer’s push
Wegovy and Zepbound costs capped at $200 in new Evernorth programme
Lilly’s Kisunla marketing for Alzheimer’s authorised in Australia
